Brian Piening

Dr. Brian Piening

Earle A. Chiles Research Institute, Division of Providence Cancer Institute, 4805 NE Glisan St., Suite 2N88, Portland, OR 97213, USA
orcid

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 May 2024 in Nature
Verified
Journal Article
Open access
PDF file
HXHanwen Xu
Hanwen Xu
NUNaoto Usuyama
Naoto Usuyama
JBJaspreet Bagga
Jaspreet Bagga
SZSheng Zhang
Sheng Zhang
RRRajesh Rao
Rajesh Rao
HPHoifung Poon
Hoifung Poon
Digital pathology poses unique computational challenges, as a standard gigapixel slide may comprise tens of thousands of image tiles1–3. Prior models have often resorted to subsampling a small portion of tiles for each slide, thus missing the important slide-level context4. Here we present Prov-GigaPath, a whole-slide pathology foundation model pretrained on 1.3 billion 256 × 256 pathology image tiles in 171,189 whole slides from Providence, a large US health network comprising 28 cancer centres. The slides originated from more than 30,000 patients covering 31 major tissue types. To pretrain Prov-GigaPath, we propose GigaPath, a novel vision transformer architecture for pretraining gigapixel pathology slides. To scale GigaPath for slide-level learning with tens of thousands of image tiles, GigaPath adapts the newly developed LongNet5 method to digital pathology. To evaluate Prov-GigaPath, we construct a digital pathology benchmark comprising 9 cancer subtyping tasks and 17 pathomics tasks, using both Providence and TCGA data6. With large-scale pretraining and ultra-large-context modelling, Prov-GigaPath attains state-of-the-art performance on 25 out of 26 tasks, with significant improvement over the second-best method on 18 tasks. We further demonstrate the potential of Prov-GigaPath on vision–language pretraining for pathology7,8 by incorporating the pathology reports. In sum, Prov-GigaPath is an open-weight foundation model that achieves state-of-the-art performance on various digital pathology tasks, demonstrating the importance of real-world data and whole-slide modelling.

12 April 2019 in Science
Verified
Journal Article
Closed access
PDF file
FGFrancine E. Garrett-Bakelman
Francine E. Garrett-Bakelman
MDManjula Darshi
Manjula Darshi
SGStefan J. Green
Stefan J. Green
RGRuben C. Gur
Ruben C. Gur
LLLing Lin
Ling Lin
FTFred Turek
Fred Turek
What to expect after a year in space: Space is the final frontier for understanding how extreme environments affect human physiology. Following twin astronauts, one of which spent a year-long mission on the International Space Station, Garrett-Bakelman et al. examined molecular and physiological traits that may be affected by time in space (see the Perspective by Löbrich and Jeggo). Sequencing the components of whole blood revealed that the length of telomeres, which is important to maintain in dividing cells and may be related to human aging, changed substantially during space flight and again upon return to Earth. Coupled with changes in DNA methylation in immune cells and cardiovascular and cognitive effects, this study provides a basis to assess the hazards of long-term space habitation. Science , this issue p. eaau8650 ; see also p. 127

1 January 2025 in NEJM AI
Verified
Journal Article
Closed access
SZSheng Zhang
Sheng Zhang
YXYanbo Xu
Yanbo Xu
NUNaoto Usuyama
Naoto Usuyama
HXHanwen Xu
Hanwen Xu
JBJaspreet Bagga
Jaspreet Bagga
HPHoifung Poon
Hoifung Poon

18 November 2024 in Nature Methods
Verified
Journal Article
Closed access
PDF file
TZTheodore Zhao
Theodore Zhao
YGYu Gu
Yu Gu
JYJianwei Yang
Jianwei Yang
NUNaoto Usuyama
Naoto Usuyama
HLHo Hin Lee
Ho Hin Lee
SWSheng Wang
Sheng Wang

11 April 2022 in Cancer Cell
Verified
Journal Article
Closed access
CZChunhong Zheng
Chunhong Zheng
JFJoseph N. Fass
Joseph N. Fass
YSYi-Ping Shih
Yi-Ping Shih
AGAndrew J. Gunderson
Andrew J. Gunderson
NSNelson Sanjuan Silva
Nelson Sanjuan Silva
ETEric Tran
Eric Tran

15 November 2016 in Journal for ImmunoTherapy of Cancer
Verified
Journal Article
Open access
PDF file
GFGerald S. Falchook
Gerald S. Falchook
RLRom Leidner
Rom Leidner
ESElizabeth Stankevich
Elizabeth Stankevich
Brian PieningBrian Piening
Brian Piening
CBCarlo Bifulco
Carlo Bifulco
MFMatthew G. Fury
Matthew G. Fury
Background Basal cell carcinoma (BCC) and cutaneous squamous cell carcinoma (CSCC) share exposure to UV light as the dominant risk factor, and these tumors therefore harbor high mutation burdens. In other malignancies, high mutation burden has been associated with clinical benefit from therapy with antibodies directed against the Programmed Death 1 (PD-1) immune checkpoint receptor. Highly mutated tumors are more likely to express immunogenic tumor neoantigens that attract effector T cells, which can be unleashed by blockade of the PD-1 immune checkpoint. Case presentations This report describes a patient with metastatic BCC and a patient with metastatic CSCC who were treated with REGN2810, a fully human anti-PD-1 monoclonal antibody, in an ongoing phase 1 trial (NCT02383212). The CSCC patient has experienced an ongoing complete response (16+ months), and the BCC patient has experienced an ongoing partial response (12+ months). Conclusions These case reports suggest that UV-associated skin cancers, beyond melanoma, are sensitive to PD-1 blockade. Trial registration Clinicaltrials.gov NCT02383212. Registered 2 February 2015.